Drugs / 225Ac-TR2205
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07340424 | May 2025 → Apr 2027 expected | triple-negative breast carcinoma | Xiaorong Sun | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 225Ac-TR2205 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07340424 ↗ |